Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
THYROGEN |
| Manufacturer |
|
Genzyme Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Thyroid stimulating hormone (recombinant). |
| Generic Name |
|
Thyrotropin alfa 1.1mg/vial; lyophilized pwd for IM inj after reconstitution; contains mannitol. |
| Indications |
|
Adjunctive diagnostic tool for serum thyroglobin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer. Adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer. |
| Children |
|
<16yrs: not recommended. |
| Adults |
|
≥16yrs: Give by IM inj into the buttock. 0.9mg, followed by a second 0.9mg injection 24 hours later. For radioiodine imaging or remnant ablation, give radioiodine 24 hours after the final thyrogen injection. |
| Precautions |
|
See literature. Heart disease, extensive metastatic disease, or other serious underlying illnesses; increased risk of Thyrogen-induced hyperthyroidism, consider hospitalization for administration and post-administration observation. Thyroglobulin (Tg) antibodies may render Tg levels uninterpretable; consider further evaluation with thyroid hormone withdrawal scan. Previous bovine TSH treatment. Residual thyroid tissue. End-stage renal disease. Elderly (increased risk of cardiac effects). Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Nausea, headache, fatigue, influenza-like symptoms. |
| How Supplied |
2-vial kit—2 vials of Thyrogen
4-vial kit—2 vials of Thyrogen + 2 vials of diluent |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
